Pitcairn Co. Acquires 19,750 Shares of Novo Nordisk A/S $NVO

Pitcairn Co. grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 159.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,113 shares of the company’s stock after purchasing an additional 19,750 shares during the quarter. Pitcairn Co.’s holdings in Novo Nordisk A/S were worth $1,782,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. True Wealth Design LLC increased its stake in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares in the last quarter. NewSquare Capital LLC boosted its stake in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares in the last quarter. Guerra Advisors Inc acquired a new stake in Novo Nordisk A/S in the third quarter worth $25,000. Strengthening Families & Communities LLC acquired a new stake in Novo Nordisk A/S in the third quarter worth $30,000. Finally, Allianz SE increased its stake in Novo Nordisk A/S by 70.0% in the third quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after purchasing an additional 238 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised Novo Nordisk to Equal Weight, and related analyst chatter lifted the stock in earlier trading — a near-term supportive catalyst. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Neutral Sentiment: General coverage and “trending” write-ups (Zacks/Yahoo) are driving retail attention but contain no new fundamental news; these pieces can increase volume/volatility without changing long‑term fundamentals. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Be aware of ticker-noise: several press releases referencing “NVO” (Novo Resources, ASX: NVO) circulated today — these are not related to Novo Nordisk (NYSE:NVO) but can create confusion in scanners and newsfeeds. Completion of Tranche 1 of Placement and Valuation Update
• Negative Sentiment: Roche reported positive Phase II results for petrelintide (up to ~10.7% weight loss with good tolerability) and plans further development — new obesity competitors gaining efficacy/tolerability could pressure Novo Nordisk’s market share and growth expectations. Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
• Negative Sentiment: A study reporting generic Ozempic/Wegovy could be produced for under $3/month highlights potential long‑term pricing pressure and margin risk if cheaper biosimilars/generics scale globally. That raises erosion risk to high-margin GLP‑1 revenues. Generic Ozempic Could Cost Less Than $3 a Month, Study Shows
• Negative Sentiment: Regulatory scrutiny increased after the FDA issued (another) warning about marketing/ads for Ozempic/Wegovy — ongoing ad/regulatory issues could hurt promotion and patient uptake and lead to fines or stricter controls. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: Pomerantz law firm announced an investigation into Novo Nordisk investor claims, which can increase legal uncertainty and weigh on sentiment until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $38.60 on Friday. The firm has a market capitalization of $172.35 billion, a P/E ratio of 11.12 and a beta of 0.73. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $88.55. The stock has a 50 day moving average price of $51.41 and a two-hundred day moving average price of $52.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NVO shares. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. TD Cowen reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Finally, Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $53.93.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.